Botanix Pharmaceuticals Ltd (BOT) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.591x

Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has a cash flow conversion efficiency ratio of -0.591x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-48.02 Million) by net assets (AU$81.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Botanix Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)

This chart illustrates how Botanix Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Botanix Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Botanix Pharmaceuticals Ltd (1991–2025)

The table below shows the annual cash flow conversion efficiency of Botanix Pharmaceuticals Ltd from 1991 to 2025.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$81.30 Million AU$-78.58 Million -0.967x -1193.21%
2024-06-30 AU$108.73 Million AU$-8.13 Million -0.075x +85.79%
2023-06-30 AU$22.95 Million AU$-12.07 Million -0.526x +61.66%
2022-06-30 AU$8.15 Million AU$-11.18 Million -1.372x -861.49%
2021-06-30 AU$20.80 Million AU$-2.97 Million -0.143x +80.57%
2020-06-30 AU$23.64 Million AU$-17.36 Million -0.734x +96.56%
2019-06-30 AU$615.22K AU$-13.14 Million -21.360x -3410.32%
2018-06-30 AU$16.28 Million AU$-9.91 Million -0.608x +28.70%
2017-06-30 AU$5.44 Million AU$-4.64 Million -0.853x -40490.24%
2016-06-30 AU$3.18 Million AU$-6.69K -0.002x +99.79%
2015-06-30 AU$1.23 Million AU$-1.20 Million -0.980x -70.31%
2014-06-30 AU$2.24 Million AU$-1.29 Million -0.575x -238.34%
2013-06-30 AU$-2.50 Million AU$-1.04 Million 0.416x -13.19%
2012-06-30 AU$-2.33 Million AU$-1.12 Million 0.479x +54.21%
2011-06-30 AU$-2.23 Million AU$-692.97K 0.311x -35.20%
2010-06-30 AU$-1.80 Million AU$-861.12K 0.479x +125.99%
2009-06-30 AU$877.74K AU$-1.62 Million -1.844x +0.15%
2008-06-30 AU$1.29 Million AU$-2.38 Million -1.847x -94.45%
2007-06-30 AU$2.90 Million AU$-2.75 Million -0.950x +29.94%
2006-06-30 AU$2.22 Million AU$-3.01 Million -1.356x -64.76%
2005-06-30 AU$3.46 Million AU$-2.84 Million -0.823x -213.18%
2004-06-30 AU$2.24 Million AU$-589.68K -0.263x +9.32%
2002-06-30 AU$4.05 Million AU$-1.17 Million -0.290x -395.90%
2001-06-30 AU$5.69 Million AU$-332.70K -0.058x +80.44%
2000-06-30 AU$5.15 Million AU$-1.54 Million -0.299x +45.25%
1999-06-30 AU$8.08 Million AU$-4.41 Million -0.546x -218.85%
1998-06-30 AU$15.75 Million AU$7.23 Million 0.459x +547.35%
1997-06-30 AU$32.05 Million AU$-3.29 Million -0.103x -8556.45%
1996-06-30 AU$37.91 Million AU$46.00K 0.001x -99.25%
1995-06-30 AU$38.44 Million AU$6.24 Million 0.162x +68.58%
1994-06-30 AU$26.04 Million AU$2.51 Million 0.096x +25.35%
1993-06-30 AU$18.35 Million AU$1.41 Million 0.077x -39.42%
1992-06-30 AU$11.41 Million AU$1.45 Million 0.127x -15.46%
1991-06-30 AU$12.88 Million AU$1.93 Million 0.150x --

About Botanix Pharmaceuticals Ltd

AU:BOT Australia Biotechnology
Market Cap
$51.59 Million
AU$72.91 Million AUD
Market Cap Rank
#24065 Global
#778 in Australia
Share Price
AU$0.04
Change (1 day)
-5.13%
52-Week Range
AU$0.04 - AU$0.47
All Time High
AU$0.52
About

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more